Company news

Achieve Life Sciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Achieve Reports Financial Results for Third Quarter 2022 and Provides Corporate Update

November 13, 2022

Achieve Announces Early Completion of Target Enrollment in Cytisinicline e-Cigarette Cessation Trial

November 7, 2022

Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation

September 26, 2022

Achieve Reports Financial Results for Second Quarter 2022 and Provides Corporate Update

August 10, 2022

Achieve Life Sciences Announces Initiation of Phase 2 ORCA-V1 Clinical Trial Evaluating Cytisinicline for Nicotine e-cigarette Cessation

June 28, 2022

Achieve Life Sciences Awarded Grant from the National Institutes of Health to Conduct Phase 2 Trial of Cytisinicline in Nicotine e-cigarette Users

May 31, 2022

Achieve Life Sciences Announces Participation at LD Micro Invitational Conference

May 25, 2022

Achieve Reports Financial Results for First Quarter 2022 and Provides Corporate Update

May 11, 2022

Achieve Life Sciences Announces Successful, Statistically Significant Smoking Cessation Results in Phase 3 ORCA-2 Clinical Trial of Cytisinicline in Adult Smokers

April 26, 2022

Achieve Life Sciences Announces Cytisinicline Presentation at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting

March 14, 2022

Achieve Life Sciences Announces Appointment of Dr. Vaughn Himes to Board of Directors

March 13, 2022

Achieve Life Sciences Announces Expansion of Manufacturing & Quality Operations Team and Granting of Inducement Award

March 10, 2022

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2021 and Provides Corporate Update

March 9, 2022

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2021 Financial Results and Host Conference Call and Webcast on March 10, 2022

February 23, 2022

Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Award

February 2, 2022

Achieve Life Sciences Announces Participation in February Investor Conferences

February 1, 2022

Achieve Life Sciences Announces Initiation of the Phase 3 ORCA-3 Clinical Trial Evaluating Cytisinicline for Smoking Cessation

January 24, 2022

Achieve Life Sciences Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking Cessation

January 3, 2022

Achieve Life Sciences Announces $25 Million Loan Facility from Silicon Valley Bank to Fund Cytisinicline Smoking Cessation Clinical Development

December 21, 2021

Achieve Life Sciences Announces Phase 3 ORCA-2 Trial of Cytisinicline in Smoking Cessation Clears Final Review by Data Safety Monitoring Committee (DSMC)

November 21, 2021

Achieve Reports Financial Results for Third Quarter 2021 and Provides Update on Cytisinicline Development

November 8, 2021

Achieve Life Sciences Announces FDA Acceptance of IND Application for Cytisinicline’s Second Planned Indication for Nicotine E-cigarette Cessation

November 1, 2021

Achieve Life Sciences to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 9, 2021

October 25, 2021

Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 21st Annual Society for Research on Nicotine & Tobacco (SRNT-E) Virtual Conference

September 13, 2021

Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Awards

August 12, 2021

Achieve Reports Financial Results for Second Quarter 2021 and Provides Corporate Update

August 10, 2021

Achieve Announces Two Patents Granted by USPTO for Novel Cytisinicline Dosing and Administration Regimen

August 10, 2021

Achieve Life Sciences to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 12, 2021

August 2, 2021

Achieve Life Sciences Awarded Grant from the National Institutes of Health (NIH) for the Evaluation of Cytisinicline in Cessation of Nicotine E-cigarette Use

July 21, 2021

Achieve Announces Completion of Target Enrollment of 750 Subjects in Phase 3 ORCA-2 Smoking Cessation Trial of Cytisinicline

June 28, 2021

Achieve Announces Allowance of U.S. Patents for Dosing and Administration of Cytisinicline for the Treatment and Prevention of Addiction

June 2, 2021

Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

May 26, 2021

Achieve Life Sciences Announces Pricing of $20 Million Underwritten Public Offering

May 24, 2021

Achieve Reports Financial Results for First Quarter 2021 and Provides Corporate Update

May 12, 2021

Achieve Life Sciences, Inc. to Host Virtual Non-Deal Roadshow on Tuesday, April 27, 2021

April 21, 2021

Achieve Announces Publication of the RAUORA Head-to-Head Non-Inferiority Clinical Trial Comparing Cytisinicline and Chantix(R) (varenicline) in Addiction

March 24, 2021

Achieve Life Sciences Announces Appointment of Dr. Bridget Martell and Dr. Cindy Jacobs to Board of Directors

March 14, 2021

Achieve Reports Financial Results for Fourth Quarter and Year-End 2020 and Provides Corporate Update

March 10, 2021

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Conference Call and Webcast on March 11, 2021

March 3, 2021

Achieve Life Sciences, Inc. Announces Closing of $17.3 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option

December 6, 2020

Achieve Life Sciences Announces Pricing of $15 Million Public Offering

December 2, 2020

Achieve Life Sciences Announces Proposed Public Offering

November 29, 2020

Achieve Reports Financial Results for Third Quarter 2020 and Provides Corporate and Cytisinicline Development Update

November 11, 2020

Achieve Life Sciences to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020

October 28, 2020

Achieve Life Sciences to Host Smoking Cessation Key Opinion Leader Virtual Roundtable on November 17th, 2020

October 26, 2020

Achieve Life Sciences Announces Start of Phase 3 ORCA-2 Clinical Trial Evaluating Cytisinicline for Smoking Cessation

October 6, 2020

Achieve Life Sciences Announces Appointment of John Bencich to Chief Executive Officer & Dr. Cindy Jacobs to President

September 29, 2020

Achieve Life Sciences Announces Results from Evaluation of Cytisinicline (cytisine) versus Chantix® (varenicline) in 5-HT3 Receptor Binding Assay Study

September 17, 2020

Achieve Announces Presentation of Investigator-Led RAUORA Trial Data Demonstrating Significantly Fewer Side Effects with Higher Quit Rates for Cytisinicline (cytisine) Compared to Chantix® (varenicline) in First Head-to-Head Comparative Study

September 17, 2020

Achieve Reports Financial Results for Second Quarter 2020 and Provides Update on Cytisinicline Development Program

August 5, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 12 decks. Every deck is listed under its year.